EDTUTC-4 New YorkLog in Sign up

VRXA
Veraxa Biotech AG
stockNASDAQ

At CloseOct 28, 2026 3:59:30 PM EDT

0.98USD-1.980%(-0.02)68,905

0.8300Bid1.2500Ask0.4200Spread

VRXA News

Day breaks

03:00 PM EDTVERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline ·

NewMediaWire

09:00 AM EDTVERAXA Biotech AG (NASDAQ: VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline ·

NetworkNewsWire

03:30 PM EDTVERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress ·

NewMediaWire

07:00 AM EDTVERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress ·

GlobeNewswire Inc.

02:58 PM EDTVERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing ·

NewMediaWire

07:00 AM EDTVERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy ·

GlobeNewswire Inc.

03:36 PM EDTVERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress ·

NewMediaWire

02:30 PM EDTVERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase ·

NewMediaWire

09:45 AM EDTVERAXA Biotech AG (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase ·

NetworkNewsWire

03:30 PM EDTVERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline ·

NewMediaWire

09:00 AM EDTVERAXA Biotech AG (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline ·

NetworkNewsWire

03:00 PM EDTVERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy ·

NewMediaWire

09:00 AM EDTVERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy ·

NetworkNewsWire

11:46 AM EDTVERAXA Biotech Designates Raju Willener as CFO ·

Exec Edge

07:00 AM EDTVERAXA Biotech Appoints Raju Willener as Chief Financial Officer ·

GlobeNewswire Inc.